Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).

News / Press Releases

: Press Releases

Press Releases

Tonix Pharmaceuticals Expands Pipeline with Mid-Stage Biologic Candidate TNX-1300 for Cocaine Intoxication

May 23, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals to Speak at the Second Chance Digital Impact Recipient Gala

May 22, 2019 • 4:19 PM EDT

Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology

May 21, 2019 • 4:15 PM EDT

Tonix Pharmaceuticals Announces Director Stepping Down

May 17, 2019 • 4:05 PM EDT

Tonix Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights

May 13, 2019 • 8:00 AM EDT

Tonix Pharmaceuticals Announces New Board Member, Daniel Goodman, M.D., MBA

May 8, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals Announces Update on the Collaborative Research and Development Agreement (CRADA) with the U.S. Army Medical Materiel Development Activity (USAMMDA)

April 23, 2019 • 1:51 PM EDT

Tonix Pharmaceuticals Announces that Breakthrough Therapy Designation Remains in Effect for Tonmya® for the Treatment of Posttraumatic Stress Disorder

April 22, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia

April 4, 2019 • 7:30 AM EDT

Tonix Pharmaceuticals to Present at Upcoming Investor Conferences

March 25, 2019 • 8:00 AM EDT

Show All

News / Press Releases : Press Releases